Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMPARISON OF SUBCUTANEOUS SUMATRIPTAN WITH USUAL ACUTE TREATMENTS FOR MIGRAINE
Autore:
BOUREAU F; CHAZOT G; EMILE J; BERTIN L; DALLENS H; BAPSTREITER; BES A; BLAS C; BRUNJOUSSET G; CHATEL M; COQUILLAT G; COTES F; DALUZEAU N; DECHY H; DEGOS C; DEREUX JF; DORDAIN G; DUCLOS H; DUMAS M; EVREUX M; GASTAUT JL; GIL R; GIRARD D; GOAS JY; GRANJON YM; HENRY P; JOYEUX O; KHALIL R; LAMBERT P; LARMANDE P; LAURENT B; LAYET A; LEJEUNNE C; MALLECOURT J; MASSIOU H; MIHOUT B; NEUSCHWANDER P; TAPIE P; RASCOL A; REIS J; ROGEZ R; SAVET JF; SERRATRICE G; TOURNILHAC M; TRISCHLER JL; VERDIE JC; VERRET JM;
Indirizzi:
GLAXO RES LABS,DEPT MED,43 RUE VINEUSE F-75116 PARIS FRANCE GLAXO RES LABS,DEPT MED F-75116 PARIS FRANCE HOP ST ANTOINE F-75571 PARIS FRANCE HOP NEUROL LYON FRANCE HOP HOTEL DIEU ANGERS FRANCE
Titolo Testata:
European neurology
fascicolo: 5, volume: 35, anno: 1995,
pagine: 264 - 269
SICI:
0014-3022(1995)35:5<264:COSSWU>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Keywords:
SUMATRIPTAN; ACUTE MIGRAINE; USUAL TREATMENTS; COMPARATIVE TRIAL; SEVERE MIGRAINE ATTACKS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
13
Recensione:
Indirizzi per estratti:
Citazione:
F. Boureau et al., "COMPARISON OF SUBCUTANEOUS SUMATRIPTAN WITH USUAL ACUTE TREATMENTS FOR MIGRAINE", European neurology, 35(5), 1995, pp. 264-269

Abstract

246 migraine patients (International Headache Society definition, 1-6severe attacks per month) were randomised into a multicentre, cross-over study comparing subcutaneous (s.c.) sumatriptan 6 mg administered by an auto-injector (Glare device) with usual acute migraine treatments. Patients were treated for 2 months or up to 12 attacks, and then crossed over to the alternative treatment for the same duration. Usual treatments were: analgesics (including combinations), 49%; ergotamine, 24%; NSAIDs 19%; DHE, 7%. Rescue medication was allowed 2 h after the first dose. Headache was assessed on a 4-point self-rating scale (0: none, 1: mild, 2: moderate, 3: severe). Other migraine symptoms were assessed as present or absent, Quality of life was assessed before the study and at the end of each treatment period, Two hundred and seventeen patients were eligible for the cross-over analysis, At 2 h post-dosing, an average of 78% of attacks per patient were successfully relieved (grade 3 or 2 to 1 or 0) by s.c. sumatriptan, compared with 34% for the usual treatments (p < 0.001) and 63% of attacks per patient were completely relieved (grade 0) by s.c. sumatriptan compared with 15% forthe usual treatments (p < 0.001). Sumatriptan-treated patients used rescue medication for 19% of their attacks, compared to 59% for comparator drugs (p = 0.001). Results for patient preference were: s.c. sumatriptan, 85%; usual treatments, 10%; no preference, 5% (p < 0.001). Sumatriptan was significantly superior to comparator drugs for all other efficacy end-points (p < 0.001). Improvements in quality of life scores were 3 times higher in sumatriptan-treated patients than in those taking usual treatments (p < 0.0001); the tolerability of both treatments was good, In conclusion, s.c. sumatriptan was superior to the usual acute treatments for both the relief of all migraine symptoms and the improvement in quality of life.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 00:35:18